Halozyme Expands ENHANZE Deal With Argenx to Eight Targets
HALO sits 80% above its 52-week low of $61.225.
Summary
Halozyme expanded its ENHANZE collaboration with argenx, adding two undisclosed therapeutic targets and raising the total licensed targets from six to eight. The deal builds on the partnership that produced VYVGART Hytrulo, a key royalty driver in Halozyme's record Q2. Halozyme will receive milestone payments and royalties on net sales of any products using ENHANZE for the new targets. The expansion reinforces the ENHANZE platform's commercial reach, now with 10 products across more than 100 markets. No financial terms were disclosed, but the added targets deepen a high-margin royalty stream.
At the time of this announcement, HALO was trading at $110.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $61.23 to $116.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.